<DOC>
	<DOCNO>NCT00920452</DOCNO>
	<brief_summary>The purpose study evaluate document appropriate clinical performance new 4-SITE Header / Lead interface TELIGEN 100 HE 4-SITE ( VR DR ) implantable cardioverter defibrillator ( ICD ) PGs ( Models F103 ; F111 ) , COGNIS 100 HE 4-SITE cardiac resynchronization therapy ICD ( CRT-D ) PG ( Model P108 ) connect RELIANCE Quadripolar ( 4-SITE ) defibrillation lead . Appropriate clinical performance system components 4-SITE system new 4-SITE header / lead interface evaluate documented already previously conduct COGNIS TELIGEN 100 HE FIELD FOLLOWING STUDY , The COGENT-4 Field Following Study . Data collect may use support international regulatory submission include FDA Japanese Ministry Health , Labour Welfare .</brief_summary>
	<brief_title>The 4-SITE Field Following Study ( 4-SITE FF )</brief_title>
	<detailed_description>The following device use ( CE-marked ) : - TELIGEN 100 HE 4-SITE ( Single Dual Chamber ICD ) - Model Number : F103 ( Quadripolar , VR ) ; - Model Number : F111 ( Quadripolar , IS-1 , DR ) - COGNIS 100 HE 4-SITE ( CRT-D ) Model Number : P108 ( Quadripolar , IS-1 , IS-1 ) - RELIANCE 4-SITE lead ( 12 different model number total show table )</detailed_description>
	<criteria>Study Specific : ICD / CRTD Indication accord normal clinical practice Patients receive : single dual chamber 4SITE compatible ICD 4SITE compatible CRTD one RELIANCE 4SITE defibrillation lead Patients currently implant pacemaker upgrade 4SITE compatible ICD CRTD ( 4SITE header ) one RELIANCE 4SITE defibrillation lead General : Willing capable providing inform consent undergo 4SITE system implant , participate test associate clinical investigation approve clinical investigational centre interval define protocol Geographically stable patient available followup study centre Age 18 , legal age give inform consent specific national law Study Specific : ICD CRTD Patients schedule device replacement CRM Patients would need lead adaptor All patient active nonactive defibrillation lead 4SITE General : Not willing capable providing informed consent , undergoing device implant , participate test associate clinical investigation ( include VT/VF shock conversion ) approve clinical investigational centre interval define protocol Patients NYHA Class IV last 3 month Patients preexist disease , may confound study result Patients currently require dialysis , Cancer patient Patients drug and/or alcohol abuse history Life expectancy &lt; 12 month ( expect heart transplant within 12 month ) Patients Heart Transplant List Women pregnant plan become pregnant . Method assessment per physician discretion . Enrolled concurrent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>implantable cardioverter defibrillator ( ICD )</keyword>
	<keyword>defibrillation lead , cardiac resynchronization therapy ( CRT )</keyword>
</DOC>